Anlotinib specifically suppresses the expression of TFRC in HCC cells via the PI3K/AKT/HIF‐α pathway and consequently leads to the upregulation of CXCL14 gene expression within these cells. This evidence concerns the gene AKT1 and hepatocellular carcinoma.